Anticipating and treating opioidassociated adverse effects

Bibliography

• REISINE T, PASTERNAK G: Opioid Analgesics and Antagonists. In: Goodman & Cilmarr's The Pharmacological Bash of Therapeutics. Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (Eds), McGraw-Hill, New York (1996):569–619.
   Google Scholar
• EDWARDS M: Barriers to effective pain/ symptom control. Am. J. Hosp. Palliat. Care (1998) 15:107–111.
   PubMedGoogle Scholar
• WARD SE, GOLDBERG N, MILLER-MCCAULEY V et al: Patient-related barriers to management of cancer pain. Pain (1993) 52:319–324.
   PubMed Web of Science ®Google Scholar
• JADAD AR, BROWMAN GP: The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. JAMA (1995) 274:1870–1873.
   Google Scholar
• NO AUTHORS LISTED: The management of chronic pain in patients with breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Canadian Society of Palliative Care Physicians. Canadian Association of Radiation Oncologists. CMAJ(1998) 158\(Suppl. 3):S71–S81.
   Google Scholar
• NO AUTHORS LISTED: Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum. (2002) 46:328–346.
   PubMed Web of Science ®Google Scholar
• SCHUG SA, ZECH D, GROND S: Adverse effects of systemic opioid analgesics. Drug Sal: (1992) 7:200–213.
   PubMed Web of Science ®Google Scholar
• SHIMP LA: Safety issues in the pharmacologic management of chronic pain in the elderly. Pharmacotherapy (1998) 18:1313–1322.
   PubMed Web of Science ®Google Scholar
• PORTENOY RK: Management of common opioid side effects during long-term therapy of cancer pain. Ann. Acad. Med. Singapore (1994) 23:160–170.
   PubMedGoogle Scholar
• WALSH TD: Prevention of opioid side effects. J. Pain Symptom Manage. (1990) 5:362–367.
   PubMedGoogle Scholar
• PUIG MM, MONTES A: Opioids: from receptors to clinical application. Curr. Rev Pain (1998) 2:234–241.
   Google Scholar
• LIU JG, LIAO XP, GONG ZH, QIN BY:The difference between methadone and morphine in regulation of 8-opioid receptors underlies the antagonistic effect of methadone on morphine-mediated cellular actions. Eur. j Pharmacol. (1999) 373:233–239.
   PubMed Web of Science ®Google Scholar
• GAVERIAUX-RUFF C, KIEFFER B: Opioid Receptors: Gene Structure and Function. In: Opioids in Pain Control: Basic and Clinical Aspects Stein C (Ed.), Cambridge University Press, New York (1999):1–384.
   Google Scholar
• MAYER DJ, MAO J, HOLT J, PRICE DD: Cellular mechanisms of neuropathic pain, morphine tolerance, and their interactions. Proc. Natl. Acad. Sri. USA (1999) 96:7731–7736.
   PubMed Web of Science ®Google Scholar
• •A strong account of neurogenic pain pathophysiology.
   Google Scholar
• MAO J, PRICE DD, MAYER DJ: Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain (1995) 62:259–274.
   PubMed Web of Science ®Google Scholar
• BENNETT GJ: Update on the neurophysiology of pain transmission and modulation: focus on the NMDA receptor. J. Pain Symptom Manage. (2000) 19:S2–S6.
   PubMed Web of Science ®Google Scholar
• •A good review of NMDA receptor physiology and implications in nociception.
   Google Scholar
• REGAN JM, PENG P, CHAN VW: Neurophysiology of cancer pain: from the laboratory to the clinic. Curr. Rev Pain (1999) 3:214–225.
   PubMedGoogle Scholar
• ••This review offers a complete and understandable account of nociceptive processes.
   Google Scholar
• CARPENTER KJ, CHAPMAN V, DICKENSON AH: Neuronal inhibitory effects of methadone are predominantly opioid receptor-mediated in the rat spinal cord in vivo. Eur. j Pain (2000) 4:19–26.
   PubMed Web of Science ®Google Scholar
• CODD EE, SHANK RP, SCHUPSKY JJ, RAFFA RB: Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. I Pharmacol Exp. Ther. (1995) 274:1263–1270.
   PubMed Web of Science ®Google Scholar
• RAJA SN, HAYTHORNTHWAITE JA, PAPPAGALLO M et al.: Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology (2002) 59:1015–1021.
   PubMed Web of Science ®Google Scholar
• BECK M, MIRMOHAMMADSADEGH A, FRANZ B, BLANKE J, HENGGE UR: Opioid receptors on white blood cells: effect of HIV infection and methadone treatment. Pain (2002) 98:187–194.
   PubMed Web of Science ®Google Scholar
• ANDERSON RP, FORMAN WB: Alternate routes of opioid administration in palliative care: pharmacologic and clinical concerns. J. Pharm. Care Path Symptom Manage. (1998) 6:5–21.
   Google Scholar
• CULPEPPER-MORGAN JA, INTURRISI CE, PORTENOY RK et al: Treatment of opioid-induced constipation with oral naloxone: a pilot study. Chu. Pharmacal Ther. (1992) 52:90–95.
   PubMed Web of Science ®Google Scholar
• DE LUCA A, COUPAR IM: Insights into opioid action in the intestinal tract. Pharmacal Ther. (1996) 69:103–115.
   PubMed Web of Science ®Google Scholar
• FOX-THRELKELD JE, DANIEL EE, CHRISTINCK F, HRUBY VJ, CIPRIS S, WOSKOWSKA Z: Identification of mechanisms and sites of actions of p, and 8 opioid receptor activation in the canine intestine. J. Pharmacal Exp. Ther. (1994) 268:689–700.
   PubMed Web of Science ®Google Scholar
• GONG L, MIDDLETON RK: Sublingual administration of opioids. Ann. Pharmacother. (1992) 26:1525–1527.
   PubMed Web of Science ®Google Scholar
• KRAJNIK M, ZYLICZ Z, FINLAY I, LUCZAK J, VAN SORGE AA: Potential uses of topical opioids in palliative care - report of 6 cases. Path (1999) 80:121–125.
   Google Scholar
• ROBERTS LJ, FINCH PM, GOUCKE CR, PRICE LM: Outcome of intrathecal opioids in chronic non-cancer pain. Eur. Pain (2001) 5:353–361.
   PubMed Web of Science ®Google Scholar
• CHANDLER S: Nebulized opioids to treat dyspnea. Am. J. Hosp. Palliat. Care (1999) 16:418–422.
   PubMedGoogle Scholar
• SCHNOLL SH, FINCH J: Medical education for pain and addiction: making progress toward answering a need. J. Law Med. Ethics (1994) 22:252–256.
   PubMed Web of Science ®Google Scholar
• PORTER J, JICK H: Addiction rare in patients treated with narcotics. N Erigl Med. (1980) 302:123.
   PubMed Web of Science ®Google Scholar
• ••This letter was one of the initial reports ofthe rare incidence of substance abuse of opioids by individuals in pain.
   Google Scholar
• JAMISON RN, KAUFFMAN J, KATZ NP: Characteristics of methadone maintenance patients with chronic pain. J. Path Symptom Manage. (2000) 19:53–62.
   PubMed Web of Science ®Google Scholar
• ARONOFF GM: Opioids in chronic pain management: is there a significant risk of addiction? Cum: Rev Pain (2000) 4:112–121.
   Google Scholar
• SAPER JR: Borderline personality, opioids, and naltrexone. Headache (2000) 40:765.
   PubMed Web of Science ®Google Scholar
• ROBINSON TE, BERRIDGE KC: The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction (2000) 95 (Suppl. 2):591–S117.
   Google Scholar
• VANDERAH TW, OSSIPOV MH, LAI J, MALAN TP Jr, PORRECA F: Mechanisms of opioid-induced pain and antinociceptive tolerance: descending facilitation and spinal dynorphin. Path (2001) 92:5–9.
   Google Scholar
• FIELLIN DA, O'CONNOR PG: Clinical practice. Office-based treatment of opioid-dependent patients. N Erigl J. Med. (2002) 347:817–823.
   Google Scholar
• WEISSMAN DE: Understanding pseudoaddiction. j Path Symptom Manage. (1994) 9:74.
   PubMed Web of Science ®Google Scholar
• •Explanation of how to define and identify pseudo-addiction.
   Google Scholar
• BRUERA E, WATANABE S: Psychostimulants as adjuvant analgesics. J. Pain Symptom Manage. (1994) 9:412–415.
   PubMed Web of Science ®Google Scholar
• COREY P, HECK A, WEATHERMANN R: Amphetamines to counteract opioid induced sedation. Ann. Pharmacother. (1999) 33:1362.
   PubMed Web of Science ®Google Scholar
• SLATKIN NE, RHINER M, BOLTON TM: Donepezil in the treatment of opioid-induced sedation: report of six cases. J. Path Symptom Manage. (2001) 21:425–438.
   PubMed Web of Science ®Google Scholar
• ASSOCIATION AP: Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (DSM-IV) (1994).
   Google Scholar
• LAWLOR PG: The panorama of opioid-related cognitive dysfunction in patients with cancer: a critical literature appraisal. Cancer (2002) 94:1836–1853.
   PubMed Web of Science ®Google Scholar
• BRUERA E, SCHOELLER T, MONTEJO G: Organic hallucinosis in patients receiving high doses of opiates for cancer pain. Pain (1992) 48:397–399.
   PubMed Web of Science ®Google Scholar
• SCHOR JD, LEVKOFF SE, LIPSITZ LA et al.: Risk factors for delirium in hospitalized elderly. JAMA (1992) 267:827–831.
   PubMed Web of Science ®Google Scholar
• ELIE M, COLE MG, PRIMEAU FJ, BELLAVANCE F: Delirium risk factors in elderly hospitalized patients. J. Gen. Intern. Med. (1998) 13:204–212.
   PubMed Web of Science ®Google Scholar
• LINDEMANN R: Changes in renal function with aging. Implications for treatment. Drugs Aging (1992) 2:423–431.
   PubMed Web of Science ®Google Scholar
• MCQUAY HJ, CARROLL D, FAURA CC, GAVAGHAN DJ, HAND CW, MOORE RA: Oral morphine in cancer pain: influences on morphine and metabolite concentration. Chu. Pharmacol Ther. (1990) 48:236–244.
   PubMed Web of Science ®Google Scholar
• GRAY SL, LAI KV, LARSON EB: Drug-induced cognition disorders in the elderly: incidence, prevention and management. Drug Sal: (1999) 21:101–122.
   PubMed Web of Science ®Google Scholar
• LAWLOR PG, GAGNON B, MANCINII I, ETA: Occurrence, causes, and outcome of delirium in advanced cancer patients: a prospective study. Arch. Intern. Med. (2000) 160:786–794.
   PubMed Web of Science ®Google Scholar
• HOGGER P: Adverse effects of opioid analgesic treatment are correlated with a significant elevation in plasma epinephrine in healthy humans. Eur. j Chu. Pharmacal (2000) 56:463–468.
   PubMed Web of Science ®Google Scholar
• MERCADANTE S: Pathophysiology and treatment of opioid-related myoclonus in cancer patients. Path (1998) 74:5–9.
   Google Scholar
• ••This review provides a complete and in-depth discussion of opioid-induced myoclonus pathophysiology.
   Google Scholar
• BABUL N, DARKE AC: Putative role of hydromorphone metabolites in myoclonus. Path (1992) 51:260–261.
   Google Scholar
• HAN PK, ARNOLD R, BOND G, JANSON D, ABU-ELMAGD K: Myoclonus secondary to withdrawal from transdermal fentanyl: case report and literature review. J. Path Symptom Manage. (2002) 23:66–72.
   PubMed Web of Science ®Google Scholar
• HOLDSWORTH MT, ADAMS VR, CHAVEZ CM, VAUGHAN LJ, DUNCAN MH: Continuous midazolam infusion for the management of morphine-induced myoclonus. Ann. Pharmacother. (1995) 29:25–29.
   PubMed Web of Science ®Google Scholar
• TISEO PJ, THALER HT, LAPIN J, INTURRISI CE, PORTENOY RK, FOLEY KM: Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients. Path (1995) 61:47–54.
   Google Scholar
• KAIKO RF, FOLEY KM, GRABINSKI PY et al.: Central nervous system excitatory effects of meperidine in cancer patients. Ann. Neural (1983) 13:180–185.
   PubMed Web of Science ®Google Scholar
• MORITA T, TSUNODA J, INOUE S, CHIHARA S: Contributing factors to physical symptoms in terminally-ill cancer patients. J. Pain Symptom Manage. (1999) 18:338–346.
   PubMed Web of Science ®Google Scholar
• WRIGHT AW, NOCENTE ML, SMITH MT: Hydromorphone-3-glucuronide: biochemical synthesis and preliminary pharmacological evaluation. Life Sci. (1998) 63:401–411.
   PubMed Web of Science ®Google Scholar
• DE STOUTZ ND, BRUERA E, SUAREZ-ALMAZOR M: Opioid rotation for toxicity reduction in terminal cancer patients. j Pain Symptom Manage. (1995) 10:378–384.
   PubMed Web of Science ®Google Scholar
• MARTIN WR: Pharmacology of opioids. Pharmacol. Rev (1983) 35:283–323.
   PubMed Web of Science ®Google Scholar
• WAY WL, FIELDS HL, SCHUMACHER MA: Opioid analgesics and antagonists. In: Basic and Clinical Pharmacology Katzung BG (Ed.), Lange, San Francisco (2000):512–531.
   Google Scholar
• CLEARY JF, CARBONE PP: Palliative medicine in the elderly. Cancer (1997) 80:1335–1347.
   PubMed Web of Science ®Google Scholar
• ERUSH SC: Nebulized morphine for thetreatment of dyspnea. P & T (1998) 12:603–605.
   Google Scholar
• SARHILL N, WALSH D, KHAWAM E, TROPIANO E STAHLEY MK: Nebulized hydromorphone for dyspnea in hospice care of advanced cancer. Am. I Hosp. Palliat. Care (2000) 17:389–391.
   PubMedGoogle Scholar
• ZEPPETELLA G: Nebulized morphine in the palliation of dyspnoea. Palliat. Med. (1997) 11:267–275.
   PubMed Web of Science ®Google Scholar
• PAPPAGALLO M: Incidence, prevalence, and management of opioid bowel dysfunction. Am. I Surg. (2001) 182:S11–S18.
   Google Scholar
• •An exhaustive review of OBD and treatment.
   Google Scholar
• SYKES N: The relationship between opioid use and laxative use in terminally ill cancer patients. Palliat. Med. (1998) 12:375–382.
   PubMed Web of Science ®Google Scholar
• FOSS JF: A review of the potential role of methylnaltrexone in opioid bowel dysfunction. Am. I Surg. (2001) 182:S19–S26.
   Google Scholar
• SCHMIDT WK: Alvimopan (ADL 8-2698) is a novel peripheral opioid antagonist. Am. J Surg. (2001) 182:S27–S38.
   Google Scholar
• SYKES NP: The relationship between opioid use and laxative use in terminally ill cancer patients. Palliat. Med. (1998) 12:375–382.
   PubMed Web of Science ®Google Scholar
• DAVIES A, PRENTICE W: Re: Fentanyl,morphine, and constipation. I Pain Symptom Manage. (1998) 16:141-144. Letter.
   Google Scholar
• DAENINCK PJ, BRUERA E: Reduction inconstipation and laxative requirements following opioid rotation to methadone: a report of four cases. I Pain Symptom Manage. (1999) 18:303–309.
   PubMed Web of Science ®Google Scholar
• MANCINI I, BRUERA E: Constipation in advanced cancer patients. Support. Care Cancer (1998) 6:356–364.
   PubMed Web of Science ®Google Scholar
• FALLON MT, HANKS GW: Morphine, constipation and performance status in advanced cancer patients. Palliat. Med. (1999) 13:159–160.
   PubMed Web of Science ®Google Scholar
• RAMESH PR, KUMAR KS, RAJAGOPAL MR, BALACHANDRAN P, WARRIER PK: Managing morphine-induced constipation: a controlled comparison of an Ayurvedic formulation and senna. I Pain Symptom Manage. (1998) 16:240–244.
   PubMed Web of Science ®Google Scholar
• SYKES NP: Constipation and Diarrhoea. In: Oxford Textbook of Palliative Medicine. Doyle D, Hanks GWC, Macdonald N (Eds), Oxford University Press, New York (1998):513–526.
   Google Scholar
• HERNDON CM, JACKSON KC II, HALLIN PA: Management of opioid-induced gastrointestinal effects in patients receiving palliative care. Pharmacotherapy (2002) 22:240–250.
   PubMed Web of Science ®Google Scholar
• •A review of GI adverse effects of opioids and directions for management.
   Google Scholar
• WALSH D: Pharmacological management of cancer pain. Semirr. arca (2000) 27:45–63.
   Google Scholar
• HURDON V, VIOLA R, SCHRODER C: How useful is docusate in patients at risk for constipation? A systematic review of the evidence in the chronically ill. I Pain Symptom Manage. (2000) 19:130–136.
   PubMed Web of Science ®Google Scholar
• LEDERLE FA, BUSCH DL, MATTOX KM, WEST MJ, ASKE DM: Cost-effective treatment of constipation in the elderly: a randomized double-blind comparison of sorbitol and lactulose. Am. I Med. (1990) 89:597–601.
   Web of Science ®Google Scholar
• FREEDMAN MD, SCHWARTZ HJ, ROBY R, FLEISHER S: Tolerance and efficacy of polyethylene glycol 3350/ electrolyte solution versus lactulose in relieving opiate induced constipation: a double-blinded placebo-controlled trial. Chin. Pharmacol (1997) 37:904–907.
   Google Scholar
• ATTAR A, LEMANN M, FERGUSON A et al.: Comparison of a low dose polyethylene glycol electrolyte solution with lactulose for treatment of chronic constipation. Gut (1999) 44:226–230.
   PubMed Web of Science ®Google Scholar
• JURNA I, KAISER R, KRETZ 0, BALDAUF J: Oral naloxone reduces constipation but not antinociception from oral morphine in the rat. Neurosci. Lett. (1992) 142:62–64.
   PubMed Web of Science ®Google Scholar
• LIU M, WITTBRODT E: Low-dose oral naloxone reverses opioid-induced constipation and analgesia. I Pain Symptom Manage. (2002) 23:48–53.
   PubMed Web of Science ®Google Scholar
• MEISSNER W, SCHMIDT U, HARTMANN M, KATH R, REINHART K: Oral naloxone reverses opioid-associated constipation. Pain (2000) 84:105–109.
   PubMed Web of Science ®Google Scholar
• ROBINSON BA, JOHANSSON L, SHAW J: Oral naloxone in opioid-associated constipation. Lancet (1991) 338:581–582.
   PubMed Web of Science ®Google Scholar
• SYKES NP: An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat. Med. (1996) 10:135–144.
   PubMed Web of Science ®Google Scholar
• CHESKIN LJ, CHAMI TN, JOHNSON RE, JAFFE JH: Assessment of nalmefene glucuronide as a selective gut opioid antagonist. Drug Alcohol Depend. (1995) 39:151–154.
   PubMed Web of Science ®Google Scholar
• CHOI YS, BILLINGS JA: Opioid antagonists: a review of their role in palliative care, focusing on use in opioid-related constipation. I Pain Symptom Manage. (2002) 24:71–90.
   PubMed Web of Science ®Google Scholar
• YUAN CS, FOSS JF, O'CONNOR M, TOLEDANO A, ROIZEN MF, MOSS J: Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial. Chin. Pharmacol Ther. (1996) 59:469–475.
   PubMed Web of Science ®Google Scholar
• YUAN CS, FOSS JF, OSINSKI J, TOLEDANO A, ROIZEN MF, MOSS J: The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time. Chin. Pharmacol Ther. (1997) 61:467–475.
   PubMed Web of Science ®Google Scholar
• YUAN CS, FOSS JF, O'CONNOR M et al.: Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA (2000) 283:367–372.
   Google Scholar
• AHMEDZAI S, BROOKS D: Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. Pain Symptom Manage. (1997) 13:254–261.
   PubMed Web of Science ®Google Scholar
• HEISKANEN T, KALSO E: Controlled-release oxycodone and morphine in cancer related pain. Pain (1997) 73:37–45.
   PubMed Web of Science ®Google Scholar
• CAMPORA E, MERLINI L, PACE M et al.: The incidence of narcotic-induced emesis. I Pahl Symptom Manage. (1991) 6:428–430.
   PubMed Web of Science ®Google Scholar
• BRUERA E, NEUMANN CM: Management of specific symptom complexes in patients receiving palliative care. CMAJ (1998) 158:1717–1726.
   PubMed Web of Science ®Google Scholar
• BAINES MJ: ABC of palliative care. Nausea, vomiting, and intestinal obstruction. Br Med. J. (1997) 315:1148–1150.
   Google Scholar
• DUNDEE JW, JONES PO: The prevention of analgesic-induced nausea and vomiting by cyclizine. Br J. Gin Piaci (1968) 22:379–382.
   Google Scholar
• FALLON BG: Nausea and vomiting unrelated to cancer treatment. In: Principles and Practice of Supportive Oncology Berger AM, Portenoy RK, Weissman DE (Eds), Lippincott Williams & Wilkins, Philadelphia (1998):179–190.
   Google Scholar
• ALDRETE JA: Reduction of nausea and vomiting from epidural opioids by adding droperidol to the infusate in home-bound patients. J. Pain Symptom Manage. (1995) 10:544–547.
   PubMed Web of Science ®Google Scholar
• COLE RIVI, ROBINSON F, HARVEY L, TRETHOWAN K, MURDOCH V: Successful control of intractable nausea and vomiting requiring combined ondansetron and haloperidol in a patient with advanced cancer. J. Pahl Symptom Manage. (1994) 9:48–50.
   PubMed Web of Science ®Google Scholar
• CRITCHLEY E PLACH N, GRANTHAM M et al: Efficacy of haloperidol in the treatment of nausea and vomiting in the palliative patient: a systematic review. J. Pahl Symptom Manage. (2001) 22:631–634.
   PubMed Web of Science ®Google Scholar
• REUBEN DB, MOR V: Nausea and vomiting in terminal cancer patients. Arch. Intern. Med. (1986) 146:2021–2023.
   PubMed Web of Science ®Google Scholar
• SILVERMAN DG, FREILICH J, SEVARINO FB, PAIGE D, PREBLE L, O'CONNOR TZ: Influence of promethazine on symptom-therapy scores for nausea during patient-controlled analgesia with morphine. Ariesth. Arialg. (1992) 74:735–738.
   PubMed Web of Science ®Google Scholar
• TYLER LS: Nausea and vomiting in palliative care. J. Pharm. Care Pahl Symptom Control (2000) 8:163–181.
   Google Scholar
• WALSH D, DOONA M, MOLNAR M, LIPNICKEY V: Symptom control in advanced cancer: important drugs and routes of administration. Semil. Oricol (2000) 27:69–83.
   PubMed Web of Science ®Google Scholar
• BRUERA E, SEIFERT L, WATANABE S et al.: Chronic nausea in advanced cancer patients: a retrospective assessment of a metoclopramide-based antiemetic regimen. J. Pahl Symptom Manage. (1996) 11:147–153.
   PubMed Web of Science ®Google Scholar
• STOREY E HILL HH Jr, ST LOUIS RH, TARVER EE: Subcutaneous infusions for control of cancer symptoms. J. Pahl Symptom Manage. (1990) 5:33–41.
   PubMedGoogle Scholar
• WANG JJ, TZENG JI, HO ST, CHEN JY, CHU CC, SO EC: The prophylactic effect of tropisetron on epidural morphine-related nausea and vomiting: a comparison of dexamethasone with saline. Ariesth. Arialg. (2002) 94:749–753.
   PubMed Web of Science ®Google Scholar
• SUSSMAN G, SHURMAN J, CREED MR et al.: Intravenous ondansetron for the control of opioid-induced nausea and vomiting. International 53AA3013 Study Group. Chu. Ther. (1999) 21:1216–1227.
   Google Scholar
• RUNG GW, CLAYBON L, HORD A et al: Intravenous ondansetron for postsurgical opioid-induced nausea and vomiting. 53A-255 Study Group. Ariesth. Arialg. (1997) 84:832–838.
   PubMed Web of Science ®Google Scholar
• ARCIONI R, DELLA ROCCA M, ROMANO S, ROMANO R, PIETROPAOLI P, GASPARETTO A: Ondansetron inhibits the analgesic effects of tramadol: a possible 5-HT3 spinal receptor involvement in acute pain in humans. Ariesth. Arialg. (2002) 94:1553–1557.
   PubMed Web of Science ®Google Scholar
• WITTE JLD, SHOENMAEKER B, SESSLER D, DELOOF T: The analgesic efficacy of tramadol is impaired by concurrent administration of ondansetron. Ariesth. Arialg. (2001) 92:1319–1321.
   PubMed Web of Science ®Google Scholar
• TARKKILA E TORN K, TUOMINEN M, LINDGREN L: Premedication with promethazine and transdermal scopolamine reduces the incidence of nausea and vomiting after intrathecal morphine. Acta Anaesthesia Scam/. (1995) 39:983–986.
   PubMed Web of Science ®Google Scholar
• CHESTNUTT WN, DUNDEE JW: The influence of cyclizine and perphenazine on the emetic effect of meptazinol. Eur. Anaesthesia. (1986) 3:27–32.
   PubMed Web of Science ®Google Scholar
• FERRIS FD, KERR IG, SONE M, MARCUZZI M: Transdermal scopolamine use in the control of narcotic-induced nausea. J. Pahl Symptom Manage. (1991) 6:389–393.
   PubMed Web of Science ®Google Scholar
• RIPAMONTI C, MERCADANTE S, GROFF L, ZECCA E, DE CONNO CASUCCIO A: Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial. j Pain Symptom Manage. (2000) 19:23–34.
   PubMed Web of Science ®Google Scholar
• ADAM J: ABC of palliative care. The last 48 hours. Br Med. J. (1997) 315:1600–1603.
   Google Scholar
• SKINNER J, SKINNER A: Levomepromazine for nausea and vomiting in advanced cancer. Hosp. Med. (1999) 60:568–570.
   PubMed Web of Science ®Google Scholar
• THOMPSON DR: Narcotic analgesic effects on the sphincter of Oddi: a review of the data and therapeutic implications in treating pancreatitis. Am. J. Castroenterol (2001) 96:1266–1272.
   PubMed Web of Science ®Google Scholar
• LEE E CUNDIFF D: Meperidine versus morphine in pancreatitis and cholecystitis. Arch. Intern. Med. (1998) 158:2399.
   PubMed Web of Science ®Google Scholar
• •A discussion of a long-standing myth in opioid utilisation for pain due to pancreatitis.
   Google Scholar
• ISENHOWER HL, MUELLER BA: Selection of narcotic analgesics for pain associated with pancreatitis. Am. J. Health Syst. Pharm. (1998) 55:480–486.
   PubMed Web of Science ®Google Scholar
• FRAGEN RJ, VILICH F, SPIES SM, ERWIN WD: The effect of remifentanil on biliary tract drainage into the duodenum. Ariesth. Arialg. (1999) 89:1561–1564.
   PubMed Web of Science ®Google Scholar
• HOLLOWAY RH: Systemic pharmacomodulation of transient lower esophageal sphincter relaxations. Am. J. Med. (2001) 111(Suppl. 8A):5178–5185.
   Google Scholar
• DRENGER B, MAGORA E EVRON S, CAINE M: The action of intrathecal morphine and methadone on the lower urinary tract in the dog. J. Ural (1986) 135:852–855.
   PubMed Web of Science ®Google Scholar
• MURRAY K: Prevention of urinary retention with phenoxybenzamine during epidural morphine. Br. Med. J. (Cliri. Res. Ed.) (1984) 288:645–646.
   PubMed Web of Science ®Google Scholar
• RAWAL N, MOLLEFORS K, AXELSSON K, LINGARDH G, WIDMAN B: Naloxone reversal of urinary retention after epidural morphine. Lancet (1981) 2:1411.
   PubMed Web of Science ®Google Scholar
• BROMAGE PR: The price of intraspinal narcotic analgesia: basic constraints. Ariesth. Arialg. (1981) 60:461–463.
   PubMed Web of Science ®Google Scholar
• UPPAL GS, HAIDER TT, DWYER A, UPPAL JA: Reversible urinary retention secondary to excessive morphine delivered by an intrathecal morphine pump. Spine (1994) 19:719–720.
   PubMed Web of Science ®Google Scholar
• PETERSEN TK, HUSTED SE, RYBRO L, SCHURIZEK BA, WERNBERG M: Urinary retention during i.m. and extradural morphine analgesia. Br. J. Ariaesth. (1982) 54:1175–1178.
   Google Scholar
• HODSMAN NB, KENNY GN, MCARDLE CS: Patient controlled analgesia and urinary retention. BE j Surg. (1988) 75:212.
   PubMed Web of Science ®Google Scholar
• PETROS JG, MALLEN JK, HOWE K, RIMM EB, ROBILLARD RJ: Patient-controlled analgesia and postoperative urinary retention after open appendectomy. Surg. CyrrecoL Obstet. (1993) 177:172–175.
   PubMed Web of Science ®Google Scholar
• PETROS JG, ALAMEDDINE F, TESTA E, RIMM EB, ROBILLARD RJ: Patient-controlled analgesia and postoperative urinary retention after hysterectomy for benign disease. j Am. Coll. Surg. (1994) 179:663–667.
   PubMed Web of Science ®Google Scholar
• WANG J, PENNEFATHER S, RUSSELL G: Low-dose naloxone in the treatment of urinary retention during extradural fentanyl causes excessive reversal of analgesia. Br j Arraesth. (1998) 80:565–566.
   PubMed Web of Science ®Google Scholar
• TERRIS MK, MERGUERIAN PA: Administration of a neuromuscular blocking agent and a narcotic agent mimicking posterior urethral valves. West. j Med. (1998) 168:194–196.
   PubMedGoogle Scholar
• EVRON S, SAMUELOFF A, SIMON A, DRENGER B, MAGORA F: Urinary function during epidural analgesia with methadone and morphine in post-cesarean section patients. Pain (1985) 23:135–144.
   PubMed Web of Science ®Google Scholar
• JACOBSON L, CHABAL C, BRODY MC, WARD RJ, IRETON RC: Intrathecal methadone and morphine for postoperative analgesia: a comparison of the efficacy, duration, and side effects. Anesthesiology (1989) 70:742–746.
   PubMed Web of Science ®Google Scholar
• GEDNEY JA, LIU EH: Side-effects of epidural infusions of opioid bupivacaine mixtures. Anaesthesia (1998) 53:1148–1155.
   PubMed Web of Science ®Google Scholar
• HUSTED S, DJURHUUS JC, HUSEGAARD HC, JEPSEN J, MORTENSEN J: Effect of postoperative extradural morphine on lower urinary tract function. Acta ArraesthesioL Land. (1985) 29:183–185.
   PubMed Web of Science ®Google Scholar
• DURANT PA, YAKSH TL: Drug effects on urinary bladder tone during spinal morphine-induced inhibition of the micturition reflex in unanesthetized rats. Anesthesiology (1988) 68:325–334.
   PubMed Web of Science ®Google Scholar
• BROMAGE PR, CAMPORESI EM, DURANT PA, NIELSEN CH: Nonrespiratory side effects of epidural morphine. Arresth. Arralg. (1982) 61:490–495.
   PubMed Web of Science ®Google Scholar
• COUSINS MJ, MATHER LE: Intrathecal and epidural administration of opioids. Anesthesiology (1984) 61:276–310.
   PubMed Web of Science ®Google Scholar
• KJELLBERG F, TRAMER MR: Pharmacological control of opioid-induced pruritus: a quantitative systematic review of randomized trials. Eur. j ArraesthesioL (2001) 18:346–357.
   PubMed Web of Science ®Google Scholar
• RAWAL N, NUUTINEN L, RAJ PP et al.: Behavioral and histopathologic effects following intrathecal administration of butorphanol, sufentanil, and nalbuphine in sheep. Anesthesiology (1991) 75:1025–1034.
   PubMed Web of Science ®Google Scholar
• JINKS SL, CARSTENS E: Superficial dorsal horn neurons identified by intracutaneous histamine: chemonociceptive responses and modulation by morphine. j NeurophysioL (2000) 84:616–627.
   PubMed Web of Science ®Google Scholar
• CHEN JC, SMITH ER, CAHILL M, COHEN R, FISHMAN JB: The opioid receptor binding of dezocine, morphine, fentanyl, butorphanol and nalbuphine. Life Sri. (1993) 52:389–396.
   PubMed Web of Science ®Google Scholar
• CHARULUXANANAN S, KYOKONG 0, SOMBOONVIBOON W, LERTMAHARIT S, NGAMPRASERTWONG P, NIMCHAROENDEE K: Nalbuphine versus propofol for treatment of intrathecal morphine-induced pruritus after cesarean delivery. Arresth. Arralg. (2001) 93:162–165.
   PubMed Web of Science ®Google Scholar
• FRIEDMAN JD, DELLO BUONO FA: Opioid antagonists in the treatment of opioid-induced constipation and pruritus. Ann. Pharmacother. (2001) 35:85–91.
   PubMed Web of Science ®Google Scholar
• ZYLICZ Z, SMITS C, KRAJNIK M: Paroxetine for pruritus in advanced cancer. J. Pain Symptom Manage. (1998) 16:121–124.
   PubMed Web of Science ®Google Scholar
• MESTON CM, FROHLICH PF: The neurobiology of sexual function. Arch. Gen. Psychiatry (2000) 57:1012–1030.
   PubMed Web of Science ®Google Scholar
• KATZ J: Opioids and nonsteroidal analgesics. In: Pain Medicine: A Comprehensive Review Raj PP (Ed.), Mosby, St Louis (1996):1–592.
   Google Scholar
• PFAUS JG, GORZALKA BB: Opioids and sexual behavior. Neurosci. Biobehav. Rev (1987) 11:1–34.
   PubMed Web of Science ®Google Scholar
• PAICE JA, PENN RD, RYAN WG: Altered sexual function and decreased testosterone in patients receiving intraspinal opioids. j Pain Symptom Manage. (1994) 9:126–131.
   PubMed Web of Science ®Google Scholar
• MIRIN SM, MEYER RE, MEND ELSON JH, ELLINGBOE J: Opiate use and sexual function. Am. J. Psychiatry (1980) 137:909–915.
   PubMed Web of Science ®Google Scholar
• PETRY NM, BICKEL WK, PIASECKI D, MARSCH LA, BADGER GJ: Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine. Am. j Addict. (2000) 9:265–269.
   PubMed Web of Science ®Google Scholar
• YURDAYDIN C: The central opioid system in liver disease and its complications. Metab. Brain Dis. (2001) 16:79–83.
   PubMed Web of Science ®Google Scholar
• BERGASA NV, ROTHMAN RB, MUKERJEE E, VERGALLA J, JONES EA: Up-regulation of central d-opioid receptors in a model of hepatic encephalopathy: a potential mechanism for increased sensitivity to morphine in liver failure. Life Sri. (2002) 70:1701–1708.
   PubMed Web of Science ®Google Scholar
• FERENCI P, PAPPAS SC, MUNSON PJ, HENSON K, JONES EA: Changes in the status of neurotransmitter receptors in a rabbit model of hepatic encephalopathy. Hepatology (1984) 4:186–191.
   PubMed Web of Science ®Google Scholar
• HOJS R, SINKOVIC A: Rhabdomyolysis and acute renal failure following methadone abuse. Nephron (1992) 62:362.
   PubMed Web of Science ®Google Scholar
• TAN AU Jr, COHEN AH, LEVINE BS: Renal amyloidosis in a drug abuser. J. Am. Soc. NephroL (1995) 5:1653–1658.
   PubMed Web of Science ®Google Scholar
• SINGHAL PC, SHARMA P, GIBBONS N, FRANKI N, KAPASI A, WAGNER JD: Effect of morphine on renomedullary interstitial cell proliferation and matrix accumulation. Nephron (1997) 77:225–234.
   PubMedGoogle Scholar
• SHEN CH, HUNG CJ, WU CC, HUANG HW, HO WM: Rhabdomyolysis-induced acute renal failure after morphine overdose - a case report. Acta ArraesthesioL Sin. (1999) 37:159–162.
   PubMedGoogle Scholar
• SEGAL A, DOWLING JP, IRETON HJ et al.: Granulomatous glomerulonephritis in intravenous drug users: a report of three cases in oxycodone addicts. Hum. PathoL (1998) 29:1246–1249.
   PubMed Web of Science ®Google Scholar
• HILL P, DWYER K, KAY T, MURPHY B: Severe chronic renal failure in association with oxycodone addiction: a new form of flbrillary glomerulopathy. Hum. PathoL (2002) 33:783–787.
   PubMed Web of Science ®Google Scholar
• KAPASI AA, GIBBONS N, MATTANA J, SINGHAL PC: Morphine stimulates mesangial cell TNF-a and nitrite production. Inflammation (2000) 24:463–476.
   PubMed Web of Science ®Google Scholar
• RICE EK, ISBEL NM, BECKER GJ, ATKINS RC, MCMAHON LP: Heroin overdose and myoglobinuric acute renal failure. OM. NephroL (2000) 54:449–454.
   Web of Science ®Google Scholar
• WELTERS ID, MENZEBACH A, GOUMON Y et al.: Morphine inhibits NF-icB nuclear binding in human neutrophils and monocytes by a nitric oxide-dependent mechanism. Anesthesiology (2000) 92:1677–1684.
   PubMed Web of Science ®Google Scholar
• RISDAHL JM, KHANNA KV, PETERSON PK, MOLITOR TW: Opiates and infection. _J. Neurohninurrol (1998) 83:4–18.
   Google Scholar
• SHARP B, YAKSH T: Painkillers of the immune system. Nat. Med. (1997) 3:831–832.
   PubMed Web of Science ®Google Scholar
• PAGE GG, BEN-ELIYAHU S: The immune-suppressive nature of pain. Semil. arca Nurs. (1997) 13:10–15.
   PubMedGoogle Scholar
• GAVERIAUX-RUFF C, MATTHES HW, PELUSO J, KIEFFER BL: Abolition of morphine-immunosuppression in mice lacking the p,-opioid receptor gene. Proc. Natl. Acad. Li. USA (1998) 95:6326–6330.
   PubMed Web of Science ®Google Scholar
• QUANG-CANTAGREL ND, WALLACE MS, ASHAR N, MATHEWS C: Long-term methadone treatment: effect on CD4+ lymphocyte counts and HIV-1 plasma RNA level in patients with HIV infection. Eur. j Pain (2001) 5:415–420.
   PubMed Web of Science ®Google Scholar
• DONAHOE RM, VLAHOV D: Opiates as potential cofactors in progression of HIV-1 infections to AIDS. _J. Neurohninurrol. (1998) 83:77–87.
   Google Scholar